A new multiple sclerosis device steps forward

Nine companies have developed powered exoskeletons that are cleared for sale in the US, with almost all of these devices intended to aid walking by patients with spinal cord injury or stroke. But last week Ekso Bionics moved into an entirely new indication, as the FDA cleared its EksoNR robotic exoskeleton for use by multiple sclerosis patients. The clearance, more specifically for rehabilitation use in patients with MS, will significantly expand the device’s reach, Ekso said. It already claims that EksoNR is the latest-generation version of the “most clinically used” robotic exoskeleton on the market. Nearly a million people in the US are living with MS, according to the National MS Society, though only a small minority of these patients would be expected to develop mobility issues serious enough to warrant the use of an exoskeleton. News of the clearance prompted Ekso’s share price to close up 23% yesterday. Unfortunately the stock has lost 99% of its value since Ekso floated in early 2014, with sales having disappointed. The company is not profitable, and reported sales of just $2.6m in the first quarter of this year.